Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Fiji Tech Network.
Press releases published on September 8, 2025

OnTerra Systems Announces That Its RouteSavvy API PLUS Route Optimization API Is Now Available on Microsoft’s Azure Marketplace
DENVER, Sept. 08, 2025 (GLOBE NEWSWIRE) -- OnTerra Systems (www.OnTerraSystems.com), a provider of web mapping products, services …

Belite Bio Announces Up to $275 Million Upsized Private Placement Financing by Leading Healthcare Investors
Transaction led by RA Capital Management with participation from Eventide Asset Management, Marshall Wace, RTW Investments, Soleus Capital and Vestal Point Capital $125 million financing upfront with up to an additional $150 million tied to exercise of …

OSS Receives New Platform Award from Safran Federal Systems
ESCONDIDO, Calif., Sept. 08, 2025 (GLOBE NEWSWIRE) -- One Stop Systems, Inc. (OSS or the Company) (Nasdaq: OSS), a leader in rugged Enterprise Class compute for artificial intelligence (AI), machine learning (ML) and sensor processing at the edge, today …

Harrow Announces Offering of $250.0 Million Senior Unsecured Notes Due 2030
Announces Commitment for New $40 Million Revolving Credit Facility Issues Conditional Notice of Redemption of 11.875% Senior Notes due 2027 NASHVILLE, Tenn., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease …

FOREWARN to Provide Identity Verification Services to Pacific Regional Multiple Listing Service to Promote Agent Safety
BOCA RATON, Fla., Sept. 08, 2025 (GLOBE NEWSWIRE) -- FOREWARN, LLC, a red violet company (NASDAQ: RDVT) and the leading provider of real-time information solutions for real estate agents, today announced that Pacific Regional Multiple Listing Service (“ …

Sionna Therapeutics Appoints Caroline Stark Beer as Chief Business Officer
WALTHAM, Mass., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that …

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PRINCETON, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement …

OncoC4 to Present Global Pivotal Phase 3 Trial Design for Next-Generation CTLA-4 Antibody Gotistobart Monotherapy Being Co-Developed with BioNTech in NSCLC at the IASLC 2025 World Conference on Lung Cancer
PRESERVE-003 is evaluating gotistobart vs. docetaxel in patients with squamous non-small cell lung cancer (sqNSCLC) who have progressed on chemotherapy and immune checkpoint therapies Pivotal Stage II design was based on data from the Stage I part of the …

Cocrystal Pharma Receives FDA IND Clearance for Challenge Study of Oral Broad-Spectrum Protease Inhibitor CDI-988, a Potential First Antiviral for Norovirus Prevention and Treatment
There are currently no approved vaccines or treatments for norovirus infection Cocrystal’s CDI-988 is the first antiviral for the potential prevention and treatment of viral gastroenteritis caused by norovirus infections Phase 1b study is expected to start …

Real-World Evidence Supports Clinical Effectiveness of neffy® (epinephrine nasal spray) in Patients Experiencing Anaphylaxis
Findings accepted for publication in the official journal of the American College of Allergy, Asthma and Immunology About 9 out of every 10 patients experiencing anaphylaxis were effectively treated with a single dose of neffy Results suggest real-world …

BioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Following Productive Type B (End of Phase 2) Meeting with FDA
FDA alignment on Phase 3 ozuriftamab vedotin (Oz-V) trial design, including dosing regimen and endpoints to support potential accelerated approval Company continues preparations for enabling initiation of the Phase 3 study with the goal of advancing the …

NeuroNOS Granted FDA Orphan Drug Designation for Glioblastoma, the Most Common and Deadliest Primary Malignant Brain Cancer in Adults
BOSTON, Sept. 08, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a biopharmaceutical company focused on developing treatments for neurological disorders and neuro-oncology, and a subsidiary of Beyond Air (NASDAQ: XAIR), today announced that the U.S. Food and Drug …

Keros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting
LEXINGTON, Mass., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders …

Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025
Data to be presented in the Immunotherapy & Cell Therapy in Sarcoma: Emerging Frontiers session at the Connective Tissue Oncology Society (CTOS) 2025 Annual Meeting SYDNEY, AUSTRALIA, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: …

Spectral Medical Sponsors Unite for Sepsis Symposium, Chicago September 8 – 9, 2025
Company to present at session titled “Personalizing Sepsis Treatment” TORONTO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and …

Aeries Technology Caps Eight Months of Momentum with Financial Turnaround, AI-Driven GCC Innovation, and Strategic Expansion
NEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Aeries Technology, Inc. (NASDAQ: AERT), a global leader in AI-powered business transformation and Global Capability Center (GCC) services, today recapped a strong first eight months of 2025, highlighting record …

Vaxart Announces Adjournment of Special Meeting of Stockholders
Meeting adjourned to September 19, 2025 at 8:30 a.m. Pacific Time Adjournment provides stockholders with more time given changes in Board composition, additional governance change considerations and future potential disclosures Vaxart encourages all …

BullFrog AI’s bfPREP™ and bfLEAP® Platforms Deliver Real-World Impact in Eleison Pharmaceuticals Collaboration
Joint oncology conference submission planned and follow-on contract discussion underway Validates BullFrog AI’s enterprise-grade platform strategy, combining automation and human-in-the-loop oversight for scalable, trustworthy analytics GAITHERSBURG, Md., …

Genius Group appoints Saifedean Ammous as Board Advisor
SINGAPORE, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Genius Group Limited (NYSE American: GNS) (“Genius Group” or the “Company”), a leading AI-powered, Bitcoin-first education group, today announced that it has appointed Saifedean Ammous as an advisor to the …

Rezolve Ai CEO Engages Wall Street with Packed September Investor Line-Up
NEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Rezolve Ai (NASDAQ: RZLV), a leader in proprietary AI-powered commerce solutions, today announced that CEO Daniel M. Wagner will present at the HC Wainwright Global Tech Investor Conference this week, …